Governments should consider offering another COVID vaccine specifically tailored to the Delta variant, according to a U.K. government advisor and Delta researcher.
The guidance comes after a new study indicated that the Delta variant was eight times less sensitive to the antibodies that vaccines provide to people compared to an earlier version of COVID from April 2020, in a lab environment.
This means it would take more antibodies from a vaccinated person to block Delta than to block this earlier version of the virus.
"We should seriously consider Delta-specific vaccines," said professor Ravi Gupta, professor of clinical microbiology at Cambridge University, member of the U.K. government's New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) virus advisory group, and lead author of the study. "The infectivity enhancement likely explains a lot of the vaccine breakthrough that we see."
Read the full article by Ed Browne here.
The variant was 27 times more likely to break through Pfizer protection from January-February and cause symptoms than it was to penetrate natural immunity from the same period.
Natural immunity from contracting coronavirus provided Israelis with longer-lasting protection against the Delta variant than two shots of the Pfizer vaccine given early this year, new Israeli research suggests.
The study by Maccabi Healthcare Service looked at individuals who had either gotten two shots of the vaccine by the end of February or tested positive for COVID-19 by that time.
It compared 46,035 Maccabi members who caught the coronavirus at some point during the pandemic and the same number of double-vaccinated people.
People who had two vaccine shots had a six-fold higher chance of getting infected with Delta than patients who hadn’t been vaccinated but previously contracted the coronavirus, according to the research.
The study, published online but not yet peer reviewed, is the largest of its kind. It doesn’t take booster shots — now widely given in Israel — into account, but given that most of the world is still giving a two-dose regimen, has international relevance.
Read the full article and study.
Refana Inc., is United States registered private corporation dedicated to finding practical and innovative solutions to the world's medical problems. By utilizing a highly collaborative open source system of research and development Refana has been able to attract world leaders in their respective scientific and medical fields to work on these problems. Through this model Refana hopes to greatly accelerate the vaccine development process for Covid-19 and help protect not only the health of the world, but also the economies and stability of nations at risk.